Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ARVN Arvinas > Key Indicators
ARVN Arvinas
39.510
-1.880-4.54%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
645.23% 77.8424 1,009.83% 130.1429 -- -- -86.61% 5.8375
Fixed Assets Turnover(T)
326.75% 6.4651 262.42% 5.1814 150.36% 3.6046 74.04% 3.0372
Total Asset Rate(T)
216.87% 0.0763 92.69% 0.0888 37.71% 0.0603 -5.05% 0.0406
ROIC
-1.98% -35.796% 10.57% -37.472% 5.15% -31.945% 3.91% -26.909%
ROE
0.02% -35.102% 11.27% -37.190% 4.85% -31.884% 2.33% -26.827%
ROA
10.18% -17.186% 37.03% -22.730% 31.57% -19.667% 29.06% -16.616%
FCF to Sales
-- -- -- 552.580% -- 818.807% -- 1187.794%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -- 5.14% -58.850%
Profitability Ratios TTM
Operating Margin
72.66% -222.837% 68.68% -252.470% 51.84% -326.605% 26.98% -418.201%
Net Margin
71.65% -225.334% 67.32% -255.873% 50.31% -326.300% 25.28% -408.994%
EBITDA Margin
72.44% -2.1204% 68.33% -2.3985% 51.17% -3.0963% 25.10% -3.9593%
R & D Expense Ratio
-62.99% 248.530% -60.70% 265.310% -44.36% 320.340% -22.27% 386.300%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-69.47% 74.310% -62.28% 87.160% -47.48% 106.270% -24.92% 131.910%
Financial Health Ratios
Long-Term Debt to Equity Ratio
28.72% 0.660% -9.04% 0.686% -23.91% 0.705% 3.79% 0.499%
Total Assets to Common Equity
9.43% 214.771% 89.91% 209.812% 85.70% 205.765% 81.14% 202.328%
Debt to Asset Ratio
46.07% 0.949% -2.51% 0.940% -16.40% 0.940% 1.67% 0.640%
Current Ratio
-38.24% 5.334 -61.50% 5.7783 -62.82% 6.1218 -58.58% 5.9324
Quick Ratio
-38.63% 5.2228 -60.98% 5.673 -62.92% 6.0298 -58.87% 5.8399
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- 14.35% 48.281%
Revenue CAGR(5Y)
-- -- -- -- -- -- -- 47.588%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist